Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–ProducingEnterobacterales: A Multicenter, Open-Label, Randomized

Post time Yesterday 11:23

journal：Clinical Infectious Diseases

Authors：Jun-Won Seo; Da Young Kim; Youngmin Yoon; Young Sang Lyu; Yong Sub Na; Do Sik Moon; Na Ra Yun; Min Seok Kim; Jeong-Han Kim; Sang Woon Bae; Jian Hur; Min Hyung Kim; Yoon Soo Park; Heejung Kim; Hyungdon Lee; Younggwon On; Seok Hyeon Na; Jung Sik Yoo; Hee-Chang Jang; Dong-Min Kim

Published date：--

DOI：10.1093/cid/ciag345

PDF link：https://academic.oup.com/cid/adv ... 8539757/ciag345.pdf

Article link：https://doi.org/10.1093/cid/ciag345

Article Source：Oxford University Press (OUP)。

Remark：

Post time Yesterday 11:23

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Oxford] Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–ProducingEnterobacterales: A Multicenter, Open-Label, Randomized

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Oxford] Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–ProducingEnterobacterales: A Multicenter, Open-Label, Randomized Copy